TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alphaton Capital Corp
Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

Researchers at the National Cancer Institute demonstrated complete tumor regressions using co-administered A2B and A2A receptor antagonists with cancer vaccines across multiple cancer models, showing promising preclinical results for potential cancer immunotherapy.

Insights
VYLD   positive

Highlighted as an example of a reliable, long-term investment stock


ATON   positive

Advancing promising oncology research through subsidiary, with clear strategic goals in developing innovative cancer therapies